News|Articles|June 16, 2026

What to Expect at the 2026 APAPP National Conference

Fact checked by: Tim Smith

Explore APAPP’s Las Vegas meeting with hands-on POCUS and airway labs, COPD and ILD bootcamps, AI updates, and new therapy insights.

The Association of Pulmonary Advanced Practice Providers (APAPP) will hold its 2026 National Conference June 17–20 at the Red Rock Casino Resort & Spa in Las Vegas, Nevada. Designed specifically for nurse practitioners, physician assistants, and other advanced practice providers working across pulmonary, critical care, and sleep medicine, the conference delivers a dense four-day program mixing hands-on procedural training, CME symposia, disease-state bootcamps, and plenary discussions spanning the full scope of the pulmonary APP's clinical practice.

Related to this article

October 30th, 2026

HCPLive Five at CHEST 2026

Five CHEST 2026 interviews cover nalbuphine ER for IPF cough, tozorakimab in COPD, depemokimab remission, AD109 in OSA, and robotic bronchoscopy.

Parth M. Rali, MD, FCCP Credit: Temple Health

October 27th, 2026

Earlier PH Screening in ILD: PHINDER Data, With Parth Rali, MD

In PHINDER, IPF had the highest PVD-B65 mortality risk scores. Rali discusses why PH in ILD is missed and when to refer for right heart catheterization.

October 27th, 2026

Inside The New AHA/ACC Acute Pulmonary Embolism Categories

Parth Rali, MD, explains how the AHA/ACC A-through-E categories compare with ESC risk tiers and how hospitals can meet the class 1 PERT recommendation.

October 27th, 2026

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Colin Church, MBBS, PhD, discusses durable 6MWD and NT-proBNP signals in a TPIP open-label extension and what phase 3 needs to show next.

October 27th, 2026

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

Colin Church, MBBS, PhD, discusses 24-month open-label extension data showing TPIP remains tolerable in patients with PH-ILD, with no new safety signals.

October 23rd, 2026

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.

October 23rd, 2026

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.

October 30th, 2026

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

The plasmid DNA immunotherapy Voceryq gained FDA accelerated approval after 27% of RRP-001 patients needed no surgery for 12 months.